Pacific Edge Ltd. 2024 AR2
The report highlights Pacific Edge's operational and financial performance for the fiscal year ended March 31, 2024. The company focused on securing Medicare coverage certainty for its Cxbladder tests, achieving a 2% increase in global commercial test volumes to 27,347. Operating revenue grew 22% to $23.9 million, supported by an 18% improvement in the US average sales price to US$613. Pacific Edge also published its STRATA study demonstrating the clinical utility of Cxbladder Triage and completed its first greenhouse gas emissions inventory, achieving Toitū carbonreduce certification.
Company: Pacific Edge Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2024
Type: AR2
Pages: 69
Back to company
Pacific Edge Ltd.
Annual Report
The report highlights Pacific Edge's operational and financial performance for the fiscal year ended March 31, 2024. The company focused on securing Medicare coverage certainty for its Cxbladder tests, achieving a 2% increase in global commercial test volumes to 27,347. Operating revenue grew 22% to $23.9 million, supported by an 18% improvement in the US average sales price to US$613. Pacific Edge also published its STRATA study demonstrating the clinical utility of Cxbladder Triage and completed its first greenhouse gas emissions inventory, achieving Toitū carbonreduce certification.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2024
Published
Jun 27, 2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women on Board
Women in Management
Workplace Fatalities
Employees